- Home
- ANNX vs YDDL Comparison
ANNX vs YDDL Comparison
Compare ANNX & YDDL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANNX
- YDDL
- Stock Information
- Founded
- ANNX 2011
- YDDL 2014
- Country
- ANNX United States
- YDDL Philippines
- Employees
- ANNX N/A
- YDDL N/A
- Industry
- ANNX Biotechnology: Pharmaceutical Preparations
- YDDL Industrial Specialties
- Sector
- ANNX Health Care
- YDDL Consumer Discretionary
- Exchange
- ANNX Nasdaq
- YDDL Nasdaq
- Market Cap
- ANNX 334.1M
- YDDL 275.4M
- IPO Year
- ANNX 2020
- YDDL 2025
- Fundamental
- Price
- ANNX $2.92
- YDDL $3.92
- Analyst Decision
- ANNX Strong Buy
- YDDL
- Analyst Count
- ANNX 4
- YDDL 0
- Target Price
- ANNX $13.00
- YDDL N/A
- AVG Volume (30 Days)
- ANNX 1.9M
- YDDL 156.0K
- Earning Date
- ANNX 11-10-2025
- YDDL 11-25-2025
- Dividend Yield
- ANNX N/A
- YDDL N/A
- EPS Growth
- ANNX N/A
- YDDL 16.34
- EPS
- ANNX N/A
- YDDL 0.12
- Revenue
- ANNX N/A
- YDDL $53,463,785.00
- Revenue This Year
- ANNX N/A
- YDDL N/A
- Revenue Next Year
- ANNX N/A
- YDDL N/A
- P/E Ratio
- ANNX N/A
- YDDL $33.96
- Revenue Growth
- ANNX N/A
- YDDL 29.55
- 52 Week Low
- ANNX $1.29
- YDDL $3.80
- 52 Week High
- ANNX $6.93
- YDDL $8.89
- Technical
- Relative Strength Index (RSI)
- ANNX 45.55
- YDDL N/A
- Support Level
- ANNX $2.66
- YDDL N/A
- Resistance Level
- ANNX $3.03
- YDDL N/A
- Average True Range (ATR)
- ANNX 0.24
- YDDL 0.00
- MACD
- ANNX -0.04
- YDDL 0.00
- Stochastic Oscillator
- ANNX 26.98
- YDDL 0.00
About ANNX Annexon Inc.
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502 for Oral small molecule; and ANX009, for systemic autoimmune diseases.
About YDDL One and One Green Technologies. Inc Class A Ordinary Shares
One and one Green Technologies Inc is engaged in recycling, production, and trading of recycled scrap metals in the Republic of Philippines. The company process raw materials and generate final products that include copper alloy ingot, aluminum scrapes, plastic beads, and others. It provides economical and flexible solutions to the challenges of electronic waste, metal scrap and industrial recycling. By providing lower-cost alternatives for processing recycled materials, It is not only Contributing to environmental sustainability but also highlight its role as a modern and specialized recycling company.